Physician profile
Alexandra E Trudeau
NPI 1417420902
$12,182.22
in general payments reported to CMS, 2019-2025
31 companies · $4,040 in 2025
The $4,040 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $203 · 2023: $2,785 · 2024: $4,809 · 2025: $4,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,399 · Travel and Lodging: $2,189 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,398.69 |
| Travel and Lodging | $2,189.42 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,742.04 | 2021-2025 | Activa PC, Percept PC Brainsense |
| Abbvie INC. | $2,712.80 | 2023-2025 | |
| Pfizer INC. | $810.54 | 2023-2025 | |
| Ucb, INC. | $714.48 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Boston Scientific Corporation | $712.23 | 2023-2024 | Vercise |
| Abbott Laboratories | $706.64 | 2023-2025 | Infinity, Proclaim |
| Acadia Pharmaceuticals INC | $559.89 | 2023-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $552.95 | 2023-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $377.03 | 2023-2025 | Mavenclad |
| Astrazeneca Pharmaceuticals LP | $360.48 | 2021-2022 | |
| Biogen, INC. | $294.44 | 2023-2025 | Vumerity, Tysabri, Plegridy |
| Lundbeck LLC | $226.74 | 2023-2025 | Vyepti, Rexulti |
| Novartis Pharmaceuticals Corporation | $213.86 | 2024-2025 | |
| Eisai INC. | $181.30 | 2024-2025 | |
| Si-Bone, INC. | $149.15 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $112.25 | 2023-2025 | Hyqvia |
| Genentech USA, INC. | $111.89 | 2025 | Ocrevus Zunovo |
| Lilly USA, LLC | $102.36 | 2024-2025 | Kisunla, Amyvid |
| Sk Life Science, INC. | $99.37 | 2024 | Xcopri |
| Amneal Pharmaceuticals LLC | $85.84 | 2023 | Rytary |
| Azurity Pharmaceuticals, INC. | $55.26 | 2024-2025 | Horizant |
| Merz Pharmaceuticals, LLC | $54.50 | 2023-2024 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $48.95 | 2025 | Austedo Xr |
| Harmony Biosciences LLC | $39.58 | 2023-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $31.56 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $31.49 | 2025 | Lumryz |
| Cala Health, INC. | $22.62 | 2024 | Cala Kiq, Cala Trio |
| Livanova USA, INC. | $21.58 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Grifols USA, LLC | $19.80 | 2025 | Gamunex-C |
| Aucta Pharmaceuticals, INC. | $16.44 | 2024 | Motpoly Xr |
| Augmedics INC. | $14.16 | 2023 | Xvision |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Trudeau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.